Key facts
- Korsana Biosciences’s last known valuation is $243.5M (Sep 2025).
- It has raised $175.0M; the latest was PIPE ($380.0M) in Apr 2026.
- Notable investors include RA Capital Management, General Atlantic, Venrock, Wellington Management, Foresite Capital — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Korsana Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Korsana Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Korsana Biosciences
Operator of a biotechnology company intended to reduce the burden of neurodegenerative diseases by discovering and developing novel, best-in-class therapies. The company's proprietary platform, a blood-brain barrier-penetrant shuttle technology combined with specialized Fc engineering, enabling customers to access more effective Alzheimer's treatments that provide higher drug concentrations in the brain, reduce safety risks like brain swelling and offer the convenience of low-volume subcutaneous administration.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2024
- Employees
- 17
- Website
- korsana.com/
- Ownership
- Privately Held (backing)
Korsana Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Korsana Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Korsana Biosciences in its N-PORT filings yet. We sweep new filings monthly.